Viridian Therapeutics Inc... (VRDN)
NASDAQ: VRDN
· Real-Time Price · USD
14.77
0.05 (0.34%)
At close: Jun 23, 2025, 2:11 PM
0.34% (1D)
| Bid | 14.72 |
| Market Cap | 1.21B |
| Revenue (ttm) | 302K |
| Net Income (ttm) | -308.32M |
| EPS (ttm) | -3.39 |
| PE Ratio (ttm) | -4.36 |
| Forward PE | -3.95 |
| Analyst | Buy |
| Ask | 14.82 |
| Volume | 209,782 |
| Avg. Volume (20D) | 885,156 |
| Open | 14.72 |
| Previous Close | 14.72 |
| Day's Range | 14.46 - 15.01 |
| 52-Week Range | 9.90 - 27.20 |
| Beta | 0.46 |
About VRDN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRDN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Viridian Therapeutics Inc. is scheduled to release its earnings on Aug 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+7.8%
Viridian Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
6 months ago
+20.67%
Viridian Therapeutics shares are trading higher after the company announced Phase 3 results for its thyroid eye disease treatment trial.
3 weeks ago · businesswire.com
Viridian Therapeutics to Participate in Upcoming June Investor ConferencesWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
2 months ago · businesswire.com
Viridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...